These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11745907)

  • 1. Stereoselective metabolism and pharmacokinetics of tegafur.
    Damle BD; Narasimhan NI; Kaul S
    Biopharm Drug Dispos; 2001 Mar; 22(2):45-52. PubMed ID: 11745907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys.
    Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K
    J Pharm Pharmacol; 2014 Dec; 66(12):1686-97. PubMed ID: 25117829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer.
    Ho DH; Covington W; Brown N; Lin SN; Pazdur R; Huo YY; Creaven PJ; Rustum YM; Meropol NJ; Lassere Y; Kuritani J; Hayakawa T
    Cancer Chemother Pharmacol; 2000; 46(5):351-6. PubMed ID: 11127938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
    Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
    Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
    Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
    Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
    Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
    Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
    Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
    Damle B; Ravandi F; Kaul S; Sonnichsen D; Ferreira I; Brooks D; Stewart D; Alberts D; Pazdur R
    Clin Cancer Res; 2001 Mar; 7(3):517-23. PubMed ID: 11297242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
    Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.
    Ozawa S; Hamada M; Murayama N; Nakajima Y; Kaniwa N; Matsumoto Y; Fukuoka M; Sawada J; Ohno Y
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):454-8. PubMed ID: 12451471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].
    Tanimura T; Kaneshige E; Fujiwara K; Kobashi Y; Inoue K; Kono I; Sekiba K
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):349-55. PubMed ID: 3080967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].
    Takeshita M; Ishikawa H; Seki M; Ikeya T; Miyamoto Y; Izuo M; Tozuka S; Usui R; Kaneko H
    Gan No Rinsho; 1985 Oct; 31(13):1697-703. PubMed ID: 3935831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
    Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
    Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
    Hoff PM; Pazdur R; Benner SE; Canetta R
    Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enantioselectivity in the cytochrome P450-dependent conversion of tegafur to 5-fluorouracil in human liver microsomes.
    Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Yoshida K
    Pharmacol Res Perspect; 2013 Oct; 1(1):e00009. PubMed ID: 25505563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of fluoropyrimidines].
    Fujita H
    Gan To Kagaku Ryoho; 1984 Nov; 11(11):2307-15. PubMed ID: 6437341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
    Yoshisue K; Kanie S; Nishimura T; Chikamoto J; Nagayama S
    J Pharm Pharmacol; 2009 Dec; 61(12):1643-51. PubMed ID: 19958587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.